Pulmonary exacerbations in CF patients with early lung disease

Michael Anstead, Lisa Saiman, Nicole Mayer-Hamblett, Larry C. Lands, Margaret Kloster, Christopher H. Goss, Lynn Rose, Jane L. Burns, Bruce Marshall, Felix Ratjen

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Background: Current definitions of pulmonary exacerbation (PE) in cystic fibrosis are based on studies in participants with significant lung disease and may not reflect the spectrum of findings observed in younger patients with early lung disease. Methods: We used data from a recent trial assessing the efficacy of azithromycin in children to study signs and symptoms associated with PEs and related changes in lung function and weight. Results: While increased cough was present in all PEs, acute weight loss and reduction in oxygen saturation were not observed. Changes in lung function did not differ between subjects who did experience a PE and those who were exacerbation-free. Conclusions: Cough was the predominant symptom in CF patients with early lung disease experiencing a PE. There was no significant difference in mean 6-month change in lung function or weight among subjects with one or more exacerbations and those without an exacerbation.

Original languageEnglish
Pages (from-to)74-79
Number of pages6
JournalJournal of Cystic Fibrosis
Issue number1
StatePublished - Jan 2014


  • Azithromycin
  • Chronic
  • Cystic fibrosis
  • Infection
  • Lung function
  • Mild
  • Pseudomonas aeruginosa
  • Pulmonary exacerbation
  • Weight

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Pulmonary exacerbations in CF patients with early lung disease'. Together they form a unique fingerprint.

Cite this